TCIM
ODT

TIAA CREF Investment Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

TIAA CREF Investment Management’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$214K Buy
+9,685
New +$169K ﹤0.01% 2871
2018
Q3 		– Sell
-10,511
Closed -$232K – 3082
2018
Q2 		$232K Buy
+10,511
New +$245K ﹤0.01% 3007

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TIAA CREF Investment Management's ODT Position: Q1 2019 in Review

TIAA CREF Investment Management opened a new position in Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2019: 9,685 shares worth $214K. The stake represents ﹤0.01% of the portfolio and ranks #2871 among its holdings. This is a return to the name: TIAA CREF Investment Management previously reported a position in ODT as recently as Q2 2018.

TIAA CREF Investment Management first reported a position in ODT in Q2 2018 and has held it in 2 quarters since. The position peaked at $232K in Q2 2018. 57 funds tracked by Wall St. Rank hold ODT as of Q1 2019.

  • TIAA CREF Investment Management held 9,685 shares of Odonate Therapeutics, Inc. Common Stock worth $214K as of Q1 2019.
  • Odonate Therapeutics, Inc. Common Stock was a new TIAA CREF Investment Management position in Q1 2019.
  • Odonate Therapeutics, Inc. Common Stock made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2871 holding.
  • TIAA CREF Investment Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q2 2018 and has held it in 2 quarters since.
  • TIAA CREF Investment Management's Odonate Therapeutics, Inc. Common Stock position peaked at $232K in Q2 2018.
  • 57 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.